This suggests the possibility that, not only is SPARC capable of sensitising CRC cells to chemotherapy[33], [34], but higher SPARC expression may be associated with other clinical features that the clinician thinks makes the tumour less aggressive and thus not require adjunctive therapy. Here, SPARC is linked to colorectal carcinoma.